

REMARKS

Applicants respectfully request the Examiner to enter the foregoing amendments prior to examination on the merits. The amendment to the specification is made to correct a typographical error. Claims 1 – 26 are cancelled and claims 27 – 111 are presented anew.

New claims 27 – 111 are directed to nanoparticulate compositions of certain drug classes (claims 27 – 55), methods of making the compositions (claims 56 – 86), and methods of administering the same to a mammal (claims 87 – 111). Support for the recited drug classes can be found throughout the specification, for example, at page 9, lines 12 – 26. Support for the specific drugs recited in the claims can be found in Examples 1 and 2 (COX-2 inhibitor type non-steroidal anti-inflammatory drug), Examples 3 – 11 (ketoprofen), Example 12 (naproxen), Example 13 (nifedipine), and Example 14 (glipizide).

Because the foregoing amendments do not introduce new matter, entry thereof by the Examiner is respectfully requested.

Applicants await and early and favorable examination on the merits. The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date Sept 23, 2003

By Michele M. Simkin

FOLEY & LARDNER

Customer Number: 22428

Telephone: (202) 672-5538

Facsimile: (202) 672-5399

Michele M. Simkin

Attorney for Applicant

Registration No. 34,717

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.